Address correspondence to Dr M. Uri Wolf, Baycrest Health Sciences, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada, firstname.lastname@example.org.
RELATIONSHIP DISCLOSURE: Drs Wolf and Goldberg report no disclosures. Dr Freedman serves as a trustee for the World Federation of Neurology and on the editorial boards of Brain and Cognition and Journal of Parapsychology; has received support from and served on an advisory board for Eli Lilly and Company Canada and receives publishing royalties from Oxford University Press; receives research/grant support from the Alzheimer Society of Canada, Brain Canada Foundation, Centre for Aging and Brain Health Innovation, Canadian Institutes of Health Research, and Westin Brain Institute; receives support from the Behavioural Neurology Physician Recognition Covenant Fund at Baycrest, the Morris Kerzner Memorial Fund, and the Saul A. Silverman Foundation as part of the Canada International Scientific Exchange Program project; and holds stock in companies producing or planning to produce medical marijuana and is listed on a provisional patent related to methods and kits for differential diagnosis of Alzheimer disease.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Wolf, Goldberg, and Freedman discuss the unlabeled/investigational use of medications for the treatment of aggression and agitation in dementia, none of which are approved by the US Food and Drug Administration.
CONTINUUM AUDIO INTERVIEW AVAILABLE ONLINE